In 2022, the market size for neurology clinical trials is projected to expand at a compound annual growth rate (CAGR) of 5.5% during the forecast period of 2023 and 2031. Increasing neurological diseases, such as dementia, stroke, and peripheral neuropathy, as well as growing R&D investments in neurological research are largely responsible for this trend. In June 2022, for instance, the "SGT-53 in Children with Recurrent or Progressive CNS Malignancies" study was initiated. In May of 2022, a similar study titled "GB5121 in Adult Patients with Relapsed/Refractory CNS Lymphoma" was initiated. After the pandemic, an increase in the number of studies is anticipated to stimulate market expansion.
The high prevalence of neurological diseases worldwide has increased sponsors' and investors' interest in providing funding for neurological clinical studies. Neurological research has received substantial funding over the years. In March 2022, for instance, a team of researchers from Brown University, New York University, and the University of Rochester received USD 16.0 million from the NIH to support Alzheimer's disease research. Future initiatives of this nature are anticipated to foster segment market expansion.
Globally, the elderly population has grown significantly over time. By 2050, this number is projected to reach 2.1 billion, according to the World Health Organization (WHO). In 2020, there were over 1.4 billion people aged 60 and older, and this number is expected to increase to 2.1 billion by 2050. Neurological disorders such as Alzheimer's disease, stroke, and Parkinson's disease are largely attributable to the aging of the population. As of 2019, Alzheimer's disease is one of the most prevalent neurological diseases, affecting more than 50 million people worldwide. Parkinson's disease affects 10 million individuals worldwide. The high prevalence of these diseases is anticipated to increase the demand for research, which will stimulate market expansion.
To facilitate clinical trials for patients, a significant number of neurological trials are currently decentralized. For instance, Firma Clinical Research and C2N Diagnostics initiated a decentralized Alzheimer's disease diagnostic clinical trial in August 2020. Increasing adoption of such trials is anticipated to increase the interest of participants in clinical studies, thereby substantially boosting the market.
Phase III is expected to experience the highest growth rate of 5.6% CAGR over the forecast period. This expansion may be attributable to the fact that phase III clinical trials are the most expensive and involve the greatest number of participants. To determine the treatment's safety and efficacy, market participants in clinical trials are initiating phase III trials aggressively. Pfizer, for example, stated in April 2022 that it intends to open clinical trial sites to conduct phase III trials of its investigational mini-dystrophin gene therapy used to treat patients with Duchenne muscular dystrophy. Such initiatives by market participants are likely to stimulate segment expansion.
The majority of cases are inherited or caused by mutation. As of June 2022, there were only 222 studies registered for HD, the majority of which were in phases I and II, and only three were reported to be in phase IV. It is anticipated that the low number of phase IV studies and the relative lack of medication for the diseases will increase the demand for research, which will have a positive effect on the market.
In 2022, epilepsy accounted for the largest share, 22%. According to the WHO, epilepsy is one of the most prevalent neurological diseases, affecting over 65 million people worldwide. Eighty percent of all epilepsy cases occur in low- and middle-income nations. As of June 2022, ClinicalTrials.gov lists a total of 1,755 epilepsy-related studies. The segment's market is anticipated to be driven by rising awareness of epilepsy and demand for innovative treatments for the condition.
As of June 2022, ClinicalTrials.gov lists over 23,000 interventional studies related to CNS disorders. In April 2022, for instance, a feasibility study entitled Feasibility of Acquiring Hyperpolarized Imaging in Patients with Primary CNS Lymphoma was recruiting participants. All of these elements contribute to the segment market.
During the forecast period, the observational segment is projected to grow at a rate of 5.8% annually. Observational studies are routinely used to evaluate treatment effects in a variety of situations, including post-marketing drug safety assessments and when clinical trials are not feasible. In addition, as of June 2022, more than 7,900 of the total CNS condition studies listed on ClinicalTrials.gov are observational.
In January 2022, for example, the observational study titled "The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: A Danish Nationwide Registry Study" was concluded.
In the United States, companies such as Biogen and IQVIA have made continuous advances in the development of new drugs and FDA approvals for neurological disorders. Government agencies, such as the National Institute of Neurological Disorders and Strokes, fund clinical trials and numerous research programs to reduce the prevalence of neurological disorders in the United States. During the period between 2022 and 2032, the U.S. dollar opportunity growth is projected to reach $1.8 billion.
Asia-Pacific is anticipated to grow at the fastest rate over the forecast period, 6% annually. As numerous developed nations invest in the Asia Pacific region, it is the market with the highest growth rate. In comparison to North America and Europe, enrolment in clinical trials is rising in Asia. Due to the large patient pool and low trial costs, this is the case. Moreover, researchers in the region are actively developing new neurological treatments. For instance, in February 2021, scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research in India developed a small molecule called TGR 63, which could disrupt the mechanism by which neurons in Alzheimer's disease become non-functional. These research endeavors are likely to contribute to regional market expansion.
The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends, and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
The high prevalence of neurological diseases worldwide has increased sponsors' and investors' interest in providing funding for neurological clinical studies. Neurological research has received substantial funding over the years. In March 2022, for instance, a team of researchers from Brown University, New York University, and the University of Rochester received USD 16.0 million from the NIH to support Alzheimer's disease research. Future initiatives of this nature are anticipated to foster segment market expansion.
Globally, the elderly population has grown significantly over time. By 2050, this number is projected to reach 2.1 billion, according to the World Health Organization (WHO). In 2020, there were over 1.4 billion people aged 60 and older, and this number is expected to increase to 2.1 billion by 2050. Neurological disorders such as Alzheimer's disease, stroke, and Parkinson's disease are largely attributable to the aging of the population. As of 2019, Alzheimer's disease is one of the most prevalent neurological diseases, affecting more than 50 million people worldwide. Parkinson's disease affects 10 million individuals worldwide. The high prevalence of these diseases is anticipated to increase the demand for research, which will stimulate market expansion.
To facilitate clinical trials for patients, a significant number of neurological trials are currently decentralized. For instance, Firma Clinical Research and C2N Diagnostics initiated a decentralized Alzheimer's disease diagnostic clinical trial in August 2020. Increasing adoption of such trials is anticipated to increase the interest of participants in clinical studies, thereby substantially boosting the market.
Phase II Led the Market by Phase
In 2022, the phase II clinical trials segment dominated the neurology clinical trials market with a 45% revenue share. The market is segmented into Phase I, Phase II, Phase III, and Phase IV based on phase. The increasing number of industry-sponsored and non-industry-sponsored phase II clinical trials, the complexity of phase II clinical trials, and the globalization of clinical trials all contribute to the segment's growth. In the past few years, a significant number of phase I drugs have been approved. In May 2021, for instance, PharmaTher Holdings Ltd. announced that the U.S. Food and Drug Administration (FDA) had approved its Investigational New Drug (IND) application to advance the company's ketamine drug to phase II clinical trial, to study the drug's safety, efficacy, and pharmacokinetics in Parkinson's patients. Such approvals are anticipated to further boost segment growth.Phase III is expected to experience the highest growth rate of 5.6% CAGR over the forecast period. This expansion may be attributable to the fact that phase III clinical trials are the most expensive and involve the greatest number of participants. To determine the treatment's safety and efficacy, market participants in clinical trials are initiating phase III trials aggressively. Pfizer, for example, stated in April 2022 that it intends to open clinical trial sites to conduct phase III trials of its investigational mini-dystrophin gene therapy used to treat patients with Duchenne muscular dystrophy. Such initiatives by market participants are likely to stimulate segment expansion.
Epilepsy Dominated the Market by Indications
Throughout the forecast period, the Huntington's disease segment is anticipated to record the highest growth rate of 6.2%. The market is segmented by indication into epilepsy, Parkinson's disease (PD), Huntington's disease, stroke, traumatic brain injury (TBI), amyotrophic lateral sclerosis (ALS), and others. Due to the absence of treatment for Huntington's disease, there is a high demand for novel medications.The majority of cases are inherited or caused by mutation. As of June 2022, there were only 222 studies registered for HD, the majority of which were in phases I and II, and only three were reported to be in phase IV. It is anticipated that the low number of phase IV studies and the relative lack of medication for the diseases will increase the demand for research, which will have a positive effect on the market.
In 2022, epilepsy accounted for the largest share, 22%. According to the WHO, epilepsy is one of the most prevalent neurological diseases, affecting over 65 million people worldwide. Eighty percent of all epilepsy cases occur in low- and middle-income nations. As of June 2022, ClinicalTrials.gov lists a total of 1,755 epilepsy-related studies. The segment's market is anticipated to be driven by rising awareness of epilepsy and demand for innovative treatments for the condition.
Interventional Segment Dominated the Market by Study Design
In 2022, the interventional segment dominated the market for neurology clinical trials, with a 96% revenue share. The market is segmented into interventional, observational, and expanded access based on the study design. Globally, a large number of interventional studies for Central Nervous System (CNS) disorders are being conducted, which accounts for the expansion.As of June 2022, ClinicalTrials.gov lists over 23,000 interventional studies related to CNS disorders. In April 2022, for instance, a feasibility study entitled Feasibility of Acquiring Hyperpolarized Imaging in Patients with Primary CNS Lymphoma was recruiting participants. All of these elements contribute to the segment market.
During the forecast period, the observational segment is projected to grow at a rate of 5.8% annually. Observational studies are routinely used to evaluate treatment effects in a variety of situations, including post-marketing drug safety assessments and when clinical trials are not feasible. In addition, as of June 2022, more than 7,900 of the total CNS condition studies listed on ClinicalTrials.gov are observational.
In January 2022, for example, the observational study titled "The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: A Danish Nationwide Registry Study" was concluded.
North America Remains as the Global Leader
In 2022, North America dominated the neurology clinical trials market, accounting for 45.0% of its total revenue. The market for neurology clinical trials in the region is driven by the rising prevalence of neurological disorders and the presence of a large number of players in clinical trials. As the population ages and life expectancy increases, dementia will become more prevalent, with an estimated 8.4 million Americans 65 and older suffering from Alzheimer's disease or another form of dementia by 2030. There are a large number of neurological patients in the United States, which increases the need for expanding clinical trials. 5.8 million Americans were affected by Alzheimer's disease in 2020. By 2060, this number is expected to triple to 14 million.In the United States, companies such as Biogen and IQVIA have made continuous advances in the development of new drugs and FDA approvals for neurological disorders. Government agencies, such as the National Institute of Neurological Disorders and Strokes, fund clinical trials and numerous research programs to reduce the prevalence of neurological disorders in the United States. During the period between 2022 and 2032, the U.S. dollar opportunity growth is projected to reach $1.8 billion.
Asia-Pacific is anticipated to grow at the fastest rate over the forecast period, 6% annually. As numerous developed nations invest in the Asia Pacific region, it is the market with the highest growth rate. In comparison to North America and Europe, enrolment in clinical trials is rising in Asia. Due to the large patient pool and low trial costs, this is the case. Moreover, researchers in the region are actively developing new neurological treatments. For instance, in February 2021, scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research in India developed a small molecule called TGR 63, which could disrupt the mechanism by which neurons in Alzheimer's disease become non-functional. These research endeavors are likely to contribute to regional market expansion.
Domination of Top Companies to Barricade the Entry of New Entrants
The global market is comprised of a large number of multinational corporations. Most of these companies pursue regional expansions, partnerships, collaborations, and M&A activities as their primary strategies. In April 2022, Labcorp, the parent company of Covance, collaborated with Xcell Biosciences, a developer of cell and gene therapy technologies, to expand its cell & gene therapy research capabilities. Labcorp and Xcellbio will work together to improve the efficacy and safety of cell and gene therapies for Parkinson's disease, cancer, and other diseases. Novartis, Covance, Med Pace, Charles River Laboratories, Syneous Health, Icon Plc, GlaxoSmithKline, Aurora Healthcare, Biogen, IQVIA, and Others.Recent developments by leading providers of neurology clinical trials include the following:
- In June 2022, Novartis announced the publication of Zolgensma data in Nature Medicine. Children with spinal muscular atrophy (SMA) who were treated with Zolgensma were able to maintain age-appropriate motor skills such as independent sitting, standing, and walking.
- In June 2022, Biogen and Alectos Therapeutics joined forces to develop and commercialize AL01811, a small molecule therapy that could be used to treat Parkinson's disease. Alectos will receive $77.5 and $630 million in development and commercial payments, respectively, as a result of the collaboration. In addition, Biogen will be responsible for manufacturing and regulatory costs once the therapy is approved for use in clinical settings.
- In June 2022, Yale University researchers discovered that a drug developed by Bristol Myers Squibb can restore the neuronal nexus known as a synapse, which is the primary contributor to cognitive decline. According to the study, it can also restore synaptic connections in mouse models of Alzheimer's. The drug also reduced the accumulation of toxic tau protein in the brains of animals.
Historical & Forecast Period
This study report represents an analysis of each segment from 2021 to 2031 considering 2022 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2023 to 2031.The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends, and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. A key data point that enables the estimation of the Neurology Clinical Trials market is as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- A number of end users and consumption volume, price, and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Neurology Clinical Trials market and their expected impact during the forecast period.
Market Segmentation
Phase
- Phase I
- Phase II
- Phase III
- Phase IV
Study Design
- Interventional
- Observational
- Expanded access
Indication
- Epilepsy
- Parkinson’s Disease
- Huntington’s Disease
- Stroke
- Traumatic brain Injury (TBI)
- Amyotrophic Lateral Sclerosis (ALS)
- Muscle regeneration
- Other Indications
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of the Neurology Clinical Trials market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2031.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Neurology Clinical Trials market?
- Which is the largest regional market for the Neurology Clinical Trials market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Neurology Clinical Trials market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Neurology Clinical Trials market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Neurology Clinical Trials Market
2.2. Global Neurology Clinical Trials Market, By Phase, 2022 (US$ Million)
2.3. Global Neurology Clinical Trials Market, By Study Design, 2022 (US$ Million)
2.4. Global Neurology Clinical Trials Market, By Indication, 2022 (US$ Million)
2.5. Global Neurology Clinical Trials Market, By Geography, 2022 (US$ Million)
2.6. Attractive Investment Proposition by Geography, 2022
3. Neurology Clinical Trials Market: Competitive Analysis
3.1. Market Positioning of Key Neurology Clinical Trials Market Vendors
3.2. Strategies Adopted by Neurology Clinical Trials Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2022 Versus 2031
4. Neurology Clinical Trials Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Neurology Clinical Trials Market Value, 2021 - 2031, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2022 Versus 2031
5.3. Market Segmentation
5.3.1. Phase I
5.3.2. Phase II
5.3.3. Phase III
5.3.4. Phase IV
6. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2022 Versus 2031
6.3. Market Segmentation
6.3.1. Interventional
6.3.2. Observational
6.3.3. Expanded access
7. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
7.1. Market Overview
7.2. Growth & Revenue Analysis: 2022 Versus 2031
7.3. Market Segmentation
7.3.1. Epilepsy
7.3.2. Parkinson’s Disease
7.3.3. Huntington’s Disease
7.3.4. Stroke
7.3.5. Traumatic brain Injury (TBI)
7.3.6. Amyotrophic Lateral Sclerosis (ALS)
7.3.7. Muscle regeneration
7.3.8. Other Indications
8. North America Neurology Clinical Trials Market, 2021-2031, USD (Million)
8.1. Market Overview
8.2. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
8.3. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
8.4. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
8.5.Neurology Clinical Trials Market: By Region, 2021-2031, USD (Million)
8.5.1.North America
8.5.1.1. U.S.
8.5.1.1.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
8.5.1.1.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
8.5.1.1.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
8.5.1.2. Canada
8.5.1.2.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
8.5.1.2.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
8.5.1.2.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
8.5.1.3. Rest of North America
8.5.1.3.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
8.5.1.3.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
8.5.1.3.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
9. UK and European Union Neurology Clinical Trials Market, 2021-2031, USD (Million)
9.1. Market Overview
9.2. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
9.3. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
9.4. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
9.5.Neurology Clinical Trials Market: By Region, 2021-2031, USD (Million)
9.5.1.UK and European Union
9.5.1.1. UK
9.5.1.1.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
9.5.1.1.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
9.5.1.1.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
9.5.1.2. Germany
9.5.1.2.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
9.5.1.2.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
9.5.1.2.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
9.5.1.3. Spain
9.5.1.3.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
9.5.1.3.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
9.5.1.3.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
9.5.1.4. Italy
9.5.1.4.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
9.5.1.4.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
9.5.1.4.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
9.5.1.5. France
9.5.1.5.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
9.5.1.5.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
9.5.1.5.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
9.5.1.6. Rest of Europe
9.5.1.6.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
9.5.1.6.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
9.5.1.6.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
10. Asia Pacific Neurology Clinical Trials Market, 2021-2031, USD (Million)
10.1. Market Overview
10.2. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
10.3. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
10.4. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
10.5.Neurology Clinical Trials Market: By Region, 2021-2031, USD (Million)
10.5.1.Asia Pacific
10.5.1.1. China
10.5.1.1.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
10.5.1.1.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
10.5.1.1.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
10.5.1.2. Japan
10.5.1.2.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
10.5.1.2.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
10.5.1.2.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
10.5.1.3. India
10.5.1.3.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
10.5.1.3.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
10.5.1.3.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
10.5.1.4. Australia
10.5.1.4.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
10.5.1.4.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
10.5.1.4.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
10.5.1.5. South Korea
10.5.1.5.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
10.5.1.5.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
10.5.1.5.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
10.5.1.6. Rest of Asia Pacific
10.5.1.6.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
10.5.1.6.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
10.5.1.6.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
11. Latin America Neurology Clinical Trials Market, 2021-2031, USD (Million)
11.1. Market Overview
11.2. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
11.3. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
11.4. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
11.5.Neurology Clinical Trials Market: By Region, 2021-2031, USD (Million)
11.5.1.Latin America
11.5.1.1. Brazil
11.5.1.1.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
11.5.1.1.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
11.5.1.1.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
11.5.1.2. Mexico
11.5.1.2.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
11.5.1.2.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
11.5.1.2.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
11.5.1.3. Rest of Latin America
11.5.1.3.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
11.5.1.3.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
11.5.1.3.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
12. Middle East and Africa Neurology Clinical Trials Market, 2021-2031, USD (Million)
12.1. Market Overview
12.2. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
12.3. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
12.4. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
12.5.Neurology Clinical Trials Market: By Region, 2021-2031, USD (Million)
12.5.1.Middle East and Africa
12.5.1.1. GCC
12.5.1.1.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
12.5.1.1.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
12.5.1.1.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
12.5.1.2. Africa
12.5.1.2.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
12.5.1.2.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
12.5.1.2.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
12.5.1.3. Rest of Middle East and Africa
12.5.1.3.1. Neurology Clinical Trials Market: By Phase, 2021-2031, USD (Million)
12.5.1.3.1. Neurology Clinical Trials Market: By Study Design, 2021-2031, USD (Million)
12.5.1.3.1. Neurology Clinical Trials Market: By Indication, 2021-2031, USD (Million)
13. Company Profile
13.1. Novartis
13.1.1. Company Overview
13.1.2. Financial Performance
13.1.3. Product Portfolio
13.1.4. Strategic Initiatives
13.2. Covance
13.2.1. Company Overview
13.2.2. Financial Performance
13.2.3. Product Portfolio
13.2.4. Strategic Initiatives
13.3. Med pace
13.3.1. Company Overview
13.3.2. Financial Performance
13.3.3. Product Portfolio
13.3.4. Strategic Initiatives
13.4. Charles River Laboratories
13.4.1. Company Overview
13.4.2. Financial Performance
13.4.3. Product Portfolio
13.4.4. Strategic Initiatives
13.5. Syneous Health
13.5.1. Company Overview
13.5.2. Financial Performance
13.5.3. Product Portfolio
13.5.4. Strategic Initiatives
13.6. Icon Plc
13.6.1. Company Overview
13.6.2. Financial Performance
13.6.3. Product Portfolio
13.6.4. Strategic Initiatives
13.7. GlaxoSmithKline
13.7.1. Company Overview
13.7.2. Financial Performance
13.7.3. Product Portfolio
13.7.4. Strategic Initiatives
13.8. Others
13.8.1. Company Overview
13.8.2. Financial Performance
13.8.3. Product Portfolio
13.8.4. Strategic Initiatives
List of Figures
Figure 1 Global Neurology Clinical Trials Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Neurology Clinical Trials Market: Quality Assurance
Figure 5 Global Neurology Clinical Trials Market, By Phase, 2022
Figure 6 Global Neurology Clinical Trials Market, By Study Design, 2022
Figure 7 Global Neurology Clinical Trials Market, By Indication, 2022
Figure 8 Global Neurology Clinical Trials Market, By Geography, 2022
Figure 9 Market Geographical Opportunity Matrix - Global Neurology Clinical Trials Market, 2022
Figure 10 Market Positioning of Key Neurology Clinical Trials Market Players, 2022
Figure 11 Global Neurology Clinical Trials Market - Tier Analysis - Percentage of Revenues by Tier Level, 2022 Versus 2031
Figure 12 Global Neurology Clinical Trials Market, By Phase, 2022 Vs 2031, %
Figure 13 Global Neurology Clinical Trials Market, By Study Design, 2022 Vs 2031, %
Figure 14 Global Neurology Clinical Trials Market, By Indication, 2022 Vs 2031, %
Figure 15 U.S. Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 16 Canada Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 17 Rest of North America Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 18 UK Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 19 Germany Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 20 Spain Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 21 Italy Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 22 France Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 23 Rest of Europe Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 24 China Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 25 Japan Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 26 India Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 27 Australia Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 28 South Korea Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 29 Rest of Asia Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 30 Brazil Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 31 Mexico Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 32 Rest of Latin America Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 33 GCC Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 34 Africa Neurology Clinical Trials Market (US$ Million), 2021 - 2031
Figure 35 Rest of Middle East and Africa Neurology Clinical Trials Market (US$ Million), 2021 - 2031
List of Figures
Table 1 Global Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 2 Global Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 3 Global Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 4 North America Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 5 North America Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 6 North America Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 7 U.S. Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 8 U.S. Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 9 U.S. Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 10 Canada Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 11 Canada Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 12 Canada Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 13 Rest of North America Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 14 Rest of North America Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 15 Rest of North America Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 16 UK and European Union Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 17 UK and European Union Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 18 UK and European Union Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 19 UK Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 20 UK Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 21 UK Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 22 Germany Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 23 Germany Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 24 Germany Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 25 Spain Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 26 Spain Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 27 Spain Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 28 Italy Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 29 Italy Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 30 Italy Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 31 France Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 32 France Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 33 France Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 34 Rest of Europe Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 35 Rest of Europe Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 36 Rest of Europe Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 37 Asia Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 38 Asia Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 39 Asia Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 40 China Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 41 China Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 42 China Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 43 Japan Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 44 Japan Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 45 Japan Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 46 India Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 47 India Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 48 India Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 49 Australia Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 50 Australia Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 51 Australia Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 52 South Korea Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 53 South Korea Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 54 South Korea Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 55 Latin America Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 56 Latin America Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 57 Latin America Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 58 Brazil Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 59 Brazil Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 60 Brazil Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 61 Mexico Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 62 Mexico Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 63 Mexico Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 64 Rest of Latin America Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 65 Rest of Latin America Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 66 Rest of Latin America Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 67 Middle East and Africa Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 68 Middle East and Africa Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 69 Middle East and Africa Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 70 GCC Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 71 GCC Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 72 GCC Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 73 Africa Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 74 Africa Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 75 Africa Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Table 76 Rest of Middle East and Africa Neurology Clinical Trials Market By Phase, 2021-2031, USD (Million)
Table 77 Rest of Middle East and Africa Neurology Clinical Trials Market By Study Design, 2021-2031, USD (Million)
Table 78 Rest of Middle East and Africa Neurology Clinical Trials Market By Indication, 2021-2031, USD (Million)
Companies Mentioned
- Novartis
- Covance
- Med pace
- Charles River Laboratories
- Syneous Health
- Icon Plc
- GlaxoSmithKline
- Aurora healthcare
- Biogen
- IQVIA
